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Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents
are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that
disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted
such as PARP, MEK, and topoisomerase inhibitors which are currently being studied in phase III trials. Various
cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate
promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive
phase II activity will be discussed.
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Remissions after primary therapy in ovarian cancer are us-
ually short-lived. Although intially responsive to a platinum
and taxane-based therapy, recurrent disease is difficult to
treat. Furthermore, there are few approved agents to treat
recurrent ovarian cancer. Although patients that recur after
6 to 12 months of initial treatment may be retreated with a
platinum plus taxane, those who relapse earlier or develop
significant toxicity, may be given pegalated lipsomal doxo-
rubicin, gemcitabine (in combination with platinum), eto-
poside, alkeran, topotecan, and/or hexamethylmelamide
[1]. Unfortunately the response rate to these agents is gen-
erally less than 30%, and demonstrable survival benefits
have not been shown. With the introduction of targeted
drugs, such as trastuzumab in breast cancer, strategies in
drug development have focused on the development of bio-
logic agents that demonstrate selectivity for tumor tissue.Introduction
In 2010, we published on recent advances in drug
discovery for ovarian cancer [1]. Since then, multiple
drugs have either failed to advance into further develop-
ment, have newly been developed, or have demonstrated
activity in phase III trials. For example, with respect to* Correspondence: Dana.chase@chw.edu
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unless otherwise stated.bevacizumab, several positive phase III trials have
supported the use of this drug in upfront and recurrent
ovarian cancer cases yet FDA approval is pending.
Another example includes a 940 patient, phase III AGO-
OVAR16 study which proved advantageous in ovarian
cancer treatment with pazopanib, increasing median
progression-free survival (PFS) by about 5.6 months [2]. In
addition, trabectedin was previously discussed and positive
phase III activity was reported, improving PFS, and overall
response rate in a 672 patient study [3]. Lastly, phase III
results from the TRINOVA-1 trial of over 900 patients
found that trebananib (AMG 386) increased PFS as
well as reduced disease progression and death by 34%
when combined with paclitaxel. Unfortunately, several
of the drugs previously described have been found to
be inactive, or with disappointing clinical outcomes.
This review will thus highlight new drugs for ovarian
cancer that have recently demonstrated positive phase
II activity (Table 1). The ultimate goal with this type
of drug development is to achieve prolonged remission
and improved quality of life (QOL), for patients with
recurrent ovarian cancer.Targeted agents
Angiogenesis inhibitors
VEGF-dependent
Vascular endothelial growth factor (VEGF) is a signaling
molecule involved in triggering the growth of blood
vessels within cancers. The VEGF mechanism of action
encompasses binding to tyrosine kinase transmembraneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Table 1 Updates in ovarian cancer drug discovery demonstrating positive phase II activity




























Oral inhibitor of MEK-1,-2
Binimetinib (MEK162)/US20130273061
(Array BioPharma/Novartis)
Oral inhibitor of MEK-1,-2
Cytotoxic agents Etirinotecan pegol (NKTR-102)/US20090074704 (Nektar) Inhibits Topoisomerase I (IV)
Paclitaxel poliglumex (CT2103)/US20070167349 (CTI BioPharma) Mitotic inhibitor (IV)





binds EpCAM, CD3, and Fc receptor
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ating angiogenesis (Figure 1) [4]. VEGFR-2 regulates cellu-
lar VEGF interactions, making it a crucial component in
the angiogenic process. Modulating VEGF has become a
highlighted area of study with potential in therapeutic
interventions.
VEGFR-1,-2,-3 inhibitor: cediranib (AZD2171)
While multiple phase III trials of cediranib (Recentin™)
may have been disappointing for colon cancer drugFigure 1 Poly(ADP-Ribose) polymerase (PARP) inhibitors.discovery, the drug has gained noticeable attention in
the treatment of ovarian cancer [5,6]. Cediranib is a po-
tent anti-angiogenesis agent that acts by blocking the
VEGF signaling cascade via the inhibition of all three
VEGFR tyrosine kinases, thus preventing the formation
of tumor vasculature [7].
Cediranib was evaluated in combination with the
PARP inhibitor, olaparib, in the first ovarian cancer trial
to utilize two orally-administered investigational drugs
[8]. The multi-center, phase II study comparing olaparib
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olaparib (200 mg twice daily) found that the combination
had nearly doubled PFS (9 vs 17.7 months). Of the 90
platinum-sensitive or BRCA-mutation patients in the
study, significantly more had an objective response rate
(ORR) in the combination group (56% vs 84%). With these
improvements in PFS and ORR came an increase in grade
3/4 toxicities, with about ten times as many observed with
the combination (7% vs 70%) [9]. The ICON6 phase III
European trial found similar improvements in PFS and
overall survival (OS) when cediranib was combined with
platinum-based chemotherapy [10]. With these encour-
aging results, the planning of a phase III cediranib and ola-
parib combination trial is underway [8].VEGF receptor, platelet-derived and fibroblast growth
factor receptor: Nintedanib (BIBF 1120)
The additional targeting of proangiogenic receptors con-
tinues to be of interest, and has been proposed to improve
the efficacy of VEGF blockade. Nintedanib is a triple angio-
kinase inhibitor that simultaneously blocks the VEGF,
platelet-derived, and fibroblast growth factor receptors [11].
When studied in animal tumor models, nintedanib effect-
ively reduced tumor blood vessel density and integrity [12].
A randomized, placebo-controlled phase II trial evaluated
nintedanib maintenance therapy (250 mg for 36 weeks),
after chemotherapy in patients with relapsed ovarian can-
cer. Eighty-three women were enrolled and following the
treatment cycle, the PFS was 16.3% for nintedanib patients
and 5% for placebo patients. Nintedanib patients experi-
enced a much higher rate of grade 3 or 4 hepatotoxicity
(51.2%), compared to that of the placebo group (7.5%) [13].
The potential effect of nintedanib nearly tripling PFS, when
compared to the placebo, has warranted a 1,300 patient,
phase III study of this drug in the LUME-Ovar 1 trial [14].
Phase III trials of nintedanib are also currently underway
for non-small cell lung cancer and being planned for hepa-
tocellular, renal, and colorectal cancers [12].Poly (ADP-ribose) polymerase inhibitor
Olaparib (AZD2281)
Poly(ADP-ribose) polymerases (PARPs) are proteins in-
volved in the repair of DNA [15]. PARPs assist in the re-
pair of DNA single-strand breaks by repairing base
excisions. BRCA1 and BRCA2 proteins involved in DNA
recombination play crucial roles in repairing double-
strand breaks, and can do so in the setting of PARP inhib-
ition. However, PARP inhibition in BRCA-deficient cells
results in the incapability to repair DNA damage induced
by chemotherapy. In a BRCA-deficient environment, cell
death can manifest when DNA breakage is not repaired,
and the cell is exposed to such agents as PARP inhibitors
that hinder single-strand break repair (Figure 1) [16].BRCA mutations represent a minority of breast and ovar-
ian cancers. These homozygous mutations, that are unique
to the tumor cells, result in the inability to repair DNA
which then can be exclusively targeted by a PARP inhibitor,
preserving the patient’s non-tumor cells. Preclinical studies
discussed by Fong et al. [17] demonstrate that BRCA-
deficient cells were 1000-fold more sensitive to PARP inhib-
itors. Ledermann et al. supported these findings in sub-
group analysis of a 265 patient study evaluating olaparib
(400 mg) maintenance therapy in platinum-sensitive,
relapsed ovarian cancer. The original phase II study
found PFS to be significantly longer with olaparib
maintanence than placebo (8.4 vs. 4.8 months, respect-
ively) [18]. A preplanned, subgroup analysis showed pa-
tients with a BRCA mutation (BRCAm) had the greatest
clinical benefit, specifically germline BRCAm which had a
7.1 month increase in PFS and significant improvement in
QOL. They found an average 6.9 month increase in PFS,
an 8.5 month improvement in time to second disease pro-
gression, and a three month increase in OS in BRCAm pa-
tients when compared with placebo [19].
These results have initiated two phase III (SOLO) tri-
als [20]. The U.S.-based SOLO1 trial, will examine ola-
parib (300 mg twice daily) as maintenance therapy in
2,500 BRCAm ovarian cancer patients following first-
line platinum chemotherapy [21]. The European-based
SOLO2 trail will examine the same dosage of olaparib
maintenance therapy but instead in 440 BRCAm pa-
tients with platinum-sensitive, relapsed, or recurrent
ovarian cancer [22].
A separate, randomized, phase II study also found
significant improvement in PFS with the addition of
olaparib to paclitaxel and carboplatin followed by subse-
quent maintenance therapy (12.2 vs. 9.6 months pla-
cebo). The ORR remained fairly similar (64% vs. 58%),
and the most common adverse events reported in
the combination phase were alopecia, nausea, and fa-
tigue [23].Rucaparib (CO-338)
Rucaparib is an inhibitor of poly(ADP-ribose) polymer-
ases 1 and 2, and works via the same mechanism as ola-
parib described above and illustrated in Figure 1. Data
suggests that PARP inhibitors are especially effective in
patients with mutations in DNA repair mechanisms,
such as those carrying BRCA mutations [24]. The
ARIEL2 trial is investigating specific biomarkers like
these to evaluate which, if any, subgroups of the 180
ovarian cancer patients may be sensitive to rucaparib
treatment [25]. This data will be incorporated into
ARIEL3, a current, randomized, double-blind study
phase III trial comparing rucaparib treatment to placebo
in 540 ovarian cancer patients [26].
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Niraparib, like the other PARP inhibitors above in Figure 1,
blocks poly(ADP-ribose) polymerases 1 and 2 from repair-
ing single-strand breaks in damaged DNA. While most
PARP inhibitors exhibit similar catalytic inhibitory proper-
ties, it is important to note the differences in potency
among drugs in this class [27]. Many propose this dis-
crepancy is due to each drug’s individual ability to trap
the PARPs at the damaged DNA site. Interestingly, the
trapped PARP-DNA complex that forms is more cyto-
toxic than the single-strand DNA break itself, associating
the potency of PARP inhibitors to their ability to form
these complexes [27,28]. Murai, et al. demonstrated that
niraparib was the most potent of the PARP inhibitors due
to its superior ability in forming the trapped PARP-DNA
complex [28].
A large, 100 patient, phase I trial evaluated niraparib
in BRCA 1/2 mutation-carrying (BRCA-MC) patients
with high-grade serous ovarian cancer (HGSOC) (n = 49),
among others cancers. Of these ovarian cancer patients,
45% had a partial response from niraparib (60 mg daily).
The platinum-sensitive HGSOC subgroup had a response
rate almost double that of the platinum-resistant group
(60% vs. 33%, respectively), with a median time of response
of 429 compared to 340 days. The most common adverse
events were grade 1/2 anemia (48%), fatigue (42%), nausea
(42%), and thrombocytopenia (35%). The maximum toler-
ated dose was determined to be 300 mg daily [29]. Nira-
parib is currently being studied as maintenance therapy in
the randomized, phase III NOVA trial evaluating daily nir-
aparib (300 mg) in 360 patients with high grade serous,
platinum sensitive, relapsed ovarian cancer [30].
MAPK kinase (MEK-1 and −2) inhibitors
Selumetinib (AZD6244)
Selumetinib is a mitogen-activated protein kinase in-
hibitor that shows preclinical benefit in targeting the
MEK oncogenic pathway. The small molecular agent is
a protein regulator in activated oncogenic pathways
expressed in ovarian cancer patients. Results from a
phase II study indicate positive activity in the treat-
ment of ovarian cancer. Fifty-two women received two
doses of selumetinib (100 mg daily) in the clinical
trial, and grade 4 adverse events were only observed
in 3 patients (6%). Thirty-four (63%) of the women in
the study had a PFS of more than 6 months, with a
median OS of 11 months [31]. Larger phase III studies
are being planned to further investigate the use of
selumetinib as a viable treatment option in ovarian
cancer.
Binimetinib (MEK162)
Binimetinib is an oral inhibitor of MEK-1 and MEK-2,
both of which play an important role in cancer cellproliferation and survival via the RAS/RAF/MEK/ERK
signal cascade. Inhibiting this pathway is believed to
interrupt growth-factor mediated cell signaling as well
as inhibit the production of inflammatory cytokines
[32]. Binimetinib is currently the subject of nearly
twenty clinical trials, including three phase III trials in
ovarian cancer and melanoma [33]. The MILO study is an
international, randomized phase III study seeking to com-
pare binimetinib to standard chemotherapy in 300 low-
grade serous ovarian cancer (LGSOC) patients [34]. With
LGSOC representing about 10% of all ovarian cancer diag-
noses, chemotherapy response rates remain much lower in
this group than in their high-grade counterparts. Even
more so, less than 4% of recurrent LGSOC patients re-
spond to additional chemotherapy [33]. The results of the
MILO study are highly anticipated, as women with pre-
treated, recurrent LGSOC do not currently have a success-
ful treatment option [35].
Topoisomerase I inhibitors
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol is a next-generation topoisomerase I
inhibitors. Topoisomerase I inhibitors are typically semi-
synthetic derivatives of the plant extract camptothecin
that prevent DNA from unwinding and therefore impede
tumor cells from replicating [36]. When normal topo-
isomerase I inhibitors like irinotecan and belotecan are
quickly dispersed within the body, they not only damage
healthy tissues, but also have poor half-lives, and do not
sufficiently expose the tumor to the concentrated thera-
peutic agent. Etirinotecan pegol, instead connects small
cytotoxic agents to a macromolecular polymer, using spe-
cialized linkers. These linkers are then slowly metabolized,
resulting in a continuous, controlled release of the chemo-
therapy, which works as previously described by inhibiting
topoisomerase I, and thus, hindering the division of the
tumor cells. Preclinical studies have shown a 300-fold in-
crease in the chemotherapy concentration, within the
tumor, when compared to other topoisomerase I inhibi-
tors. Along with this, increased effectiveness in tumor
concentrations, the half-life of this agent has improved to
50 days, with activity in circulation throughout the entire
cell cycle [37].
Clinical trials are under investigation for the use of this
agent in various cancers, including ovarian cancer. One
phase II, open-label study evaluated etirinotecan pegol
(145 mg/m2), every 14 or 21 days in 71 women with
platinum-resistant or refractory ovarian cancer. Of patients
receiving the drug every 14 days, 27% had a RECIST re-
sponse compared to 22% for those receiving it every
21 days. CA-125 responses were 61% and 52%, respectively,
with a median time of 31 days to 50% decline in CA-125.
The most common grade 3/4 toxicities included diarrhea
(22% vs. 11%, respectively), dehydration (14% vs. 6%,
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[38]. Further investigation was encouraged by the activity
observed in these heavily pretreated patients.
A different randomized, multicenter, phase II trial
evaluated etirinotecan pegol (145 mg/m2) every 14 or
21 days in 71 women with platinum-resistant or refrac-
tory ovarian cancer. Patients who received the agent
every 14 days had a slightly higher response rate and re-
sponse duration (20% and 4.1 months, respectively)
than those who received it every 21 days (19% and
4.0 months, respectively). Median PFS and overall re-
sponse rates were higher in patients receiving the drug
every 21 days (5.3 and 11.7 months, respectively) than
those receiving it every 14 days (4.1 and 10.0 months,
respectively). The drug was well tolerated with grade 3/
4 toxicities including dehydration (24%) and diarrhea
(23%). Planning for a phase III investigation of etirinote-
can pegol (145 mg/m2) every 21 days is currently under-
way [39]. Phase III investigation in ovarian cancer has
also been encouraged by the recent, positive interim ef-
ficacy analysis in the phase III BEACON trial for meta-
static breast cancer [40].Cytotoxic agents
Mitotic Inhibitor
Paclitaxel poliglumex (CT2103)
Paclitaxel poliglumex is an agent that utilizes polyglutamate
drug delivery technology, similar to that described in etiri-
notecan pegol above. These polyglutamate molecules are
much larger than standard paclitaxel molecules, allowing
them to lodge themselves in tumor tissue through leaky
tumor vasculature. The drug remains inactive in the blood-
stream and is too large to fit through normal vasculature,
so it specifically targets only tumor cells. Once inside the
tumor tissue, the agent is slowly metabolized by the tumor
cells, resulting in the controlled release of the cytotoxic
agent. This process reduces toxicity to healthy tissues while
simultaneously increasing efficacy [41]. Paclitaxel poliglu-
mex falls into the mitotic inhibitor drug class and is under
investigation in the treatment of ovarian cancer [42].
Paclitaxel poliglumex (OPAXIO™) has completed
enrollment in a 1,100 patient, randomized phase III trial
comparing 12 cycles of maintenance therapy paclitaxel
poliglumex or paclitaxel versus no treatment [43]. The
previous phase II data that encouraged this phase III
trial came nearly 10 years ago in the study of carboplatin
with paclitaxel poliglumex in 82 ovarian cancer patients.
The study reported 98% of patients having a major tumor
response with reduction in CA-125 levels, complete re-
sponses occurring in 85% of patients, and partial response
in 12%. The most common adverse events were grade 3/4
neutropenia (92%), thrombocytopenia (55%), and neur-
opathy (23%) [44].DNA minor groove binders
Lurbinectedin (PM1183)
Lurbinectedin is a synthetic analogue of trabectedin (previ-
ously discussed) [1]. Positive phase III results were reported
for the combination of trabectedin with pegylated liposomal
doxorubicin, increasing PFS and overall response rate in
women with relapsed ovarian cancer [45]. Trabectedin be-
came the first marine-derived cancer drug, derived from
the colonial tunicate, Ecteinascidia turbinate, and marketed
in Europe and Japan as Yondelis® [46]. Lurbinectedin has
the same structure as trabectedin, differing only in the C
subunit. Soares et al. found that the modified C subunit did
not significantly alter lurbinectedin activity or cytotoxicity,
and suggested the new analogue may be useful for altering
dosages to increase antitumor activity [47]. Lurbinectedin
works by covalently binding the minor groove in DNA.
This binding causes the DNA strand to bend, increasing
the incidence of double-strand breaks while also interfering
with cell cycle processes and the nucleotide excision repair
pathway [48].
Early in vivo mouse models demonstrated that single-
agent lurbinectedin was effective in treating cisplatin-
sensitive and cisplatin-resistant ovarian tumor models.
Preclinical data also suggested that the combination of
lurbinectedin with cisplatin-combined therapy was espe-
cially effective in the cisplatin-resistant tumors [49]. A
randomized, phase II study of 81 platinum-resistant/re-
fractory ovarian cancer patients compared lurbinectedin
to topotecan and found that lurbinectedin had signifi-
cantly improved OS (10.6 vs 5.7 months), PFS (3.9 vs
2.0 months), and the overall response rate (22%). In the
lurbinectedin treatment arm, 85% of patients experienced
grade 3/4 neutropenia, which was found to be preventable
by using a G-CSF blood stimulating factor [50]. With this
encouraging data and the success of trabectedin, lurbinec-
tedin has received Orphan Drug status from the FDA and
phase III trials in platinum-resistant patients have been
planned [48,50].Therapeutic vaccines
EpCAM, CD3, and Fc receptor antibody
Catumaxomab
Catumaxomab (Removab®) is classified as a tri-
functional antibody, with a structure comprised of an
anti-EpCAM antibody and an anti-CD3 antibody. This
allows catumaxomab to bind to the antigen EpCAM on
tumor cells, the CD3 molecules on T cells, and to the Fc
receptor on accessory cells, and in doing so, trigger an
antitumor immune response [51]. Catumaxomab was
approved in Europe in 2009 for the intraperitoneal
treatment of malignant ascites in EpCAM-positive can-
cer patients, and it is currently in clinical trials in the
U.S. [52]. Approximately 10% of ascites, which is the
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cancer and called malignant ascites [53].
An open-label, phase II study of catumaxomab in pa-
tients with malignant ascites enrolled 32 women and
found almost one-fourth (22.6%) of patients had at least
a 400% increase in their platinum-free interval after
catumaxomab treatment. Patients received catumaxo-
mab (10, 20, 50, 150 μg) on days 0, 3, 7, and 10. The me-
dian OS was 3.6 months, with toxicities that were
tolerable and consistent with what would be expected
for this type of antibody [54]. Another single-arm phase
II study administered one intraoperative (10 μg) and
four postoperative (10, 20, 50, 150 μg) doses of catu-
maxomab on days 7, 10, 13, and 16. The study found a
3-year survival benefit in patients who received catu-
maxomab when compared to a match-pair control
group (respective survival rates of 85.4% and 63.4%)
[55]. This favorable survival data initiated a phase III
trial of 258 EpCAM-positive cancer patients with malig-
nant ascites [56].
Conclusions
As the inclusion of unconventional agents are increasingly
incorporated into clinical trials and practice, the hope is
that drug discovery will be encouraged in all areas of
cancer therapy, from improving our ability to predict
response to chemotherapy, to enhancing the delivery of
drugs to targeted tissues. As stated previously in an earlier
review [1], with the future of cancer treatment moving
towards a more personalized approach, the goal is that an
individual profile will be determined, and thus agents used
that target key pathways in this individual’s cancer.
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